ANRO
HEALTHCAREAlto Neuroscience Inc
$24.49-0.96 (-3.77%)PRE
Live · NYSE · May 9, Close
AI Insight
What's Moving ANRO Today?
No stock-specific AI insight has been generated for ANRO yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.15$28.44
$24.49
Fundamentals
Market Cap$858M
P/E Ratio—
EPS$-2.19
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume353K
Avg Volume (10D)—
Shares Outstanding35.1M
ANRO News
20 articles- Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual MeetingYahoo Finance·May 4, 2026
- Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant DepressionYahoo Finance·Apr 21, 2026
- Top 1% Alto Neuroscience Plummets On Its Shocking Schizophrenia MissYahoo Finance·Apr 2, 2026
- Sector Update: Health Care Stocks Softer Late AfternoonYahoo Finance·Apr 2, 2026
- Update: Alto Neuroscience Shares Fall After Phase 2 Trial of ALTO-101 Yields Statistically Insignificant DataYahoo Finance·Apr 2, 2026
- Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJMBiopharmadive·Apr 2, 2026
- Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline AdvancementsYahoo Finance·Apr 1, 2026
- Alto Neuroscience CFO Nick Smith on Firm’s $120 Million Private PlacementYahoo Finance·Mar 23, 2026
- NYSE Content Update: Alto Neuroscience Raises $120 Million to Fund Development of ALTO-207Yahoo Finance·Mar 23, 2026
- Alto Neuroscience Announces $120 Million Private Placement FinancingYahoo Finance·Mar 16, 2026
- Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business HighlightsYahoo Finance·Mar 16, 2026
- Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS ForumYahoo Finance·Mar 13, 2026
- Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancements in Psychiatric Therapies | DelveInsightYahoo Finance·Mar 11, 2026
- Alto Neuroscience Announces Participation in Upcoming Investor ConferencesYahoo Finance·Feb 23, 2026
- Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with SchizophreniaYahoo Finance·Feb 13, 2026
- Alto Neuroscience, Inc.'s (NYSE:ANRO) Intrinsic Value Is Potentially 58% Above Its Share PriceYahoo Finance·Feb 5, 2026
- Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and TreatmentYahoo Finance·Feb 3, 2026
- Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in DepressionYahoo Finance·Jan 14, 2026
- Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of NeuropsychopharmacologyYahoo Finance·Jan 13, 2026
- Alto Neuroscience, Inc. (NYSE:ANRO) is definitely on the radar of institutional investors who own 33% of the companyYahoo Finance·Dec 26, 2025
All 20 articles loaded
Price Data
Open$25.12
Previous Close$25.45
Day High$25.42
Day Low$24.75
52 Week High$28.44
52 Week Low$2.15
52-Week Range
$2.15$28.44
$24.49
Fundamentals
Market Cap$858M
P/E Ratio—
EPS$-2.19
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume353K
Avg Volume (10D)—
Shares Outstanding35.1M
About Alto Neuroscience Inc
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company is headquartered in Los Altos, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNYSE
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—